Product
zanzalintinib
Aliases
XL092
1 clinical trial
1 indication
Indication
Advanced Clear Cell Renal Cell CarcinomaClinical trial
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors.Status: Recruiting, Estimated PCD: 2026-01-01